More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.

The recall was issued due to the potential for the systems to produce artifacts during PET exams.

Bayer is acquiring two cardiac amyloidosis radiotracers from Attralus, one for PET and one for SPECT. The SPECT tracer is also a theranostic agent to both image and treat amyloidosis.

Sarah-Jane James, imaging market analyst for Signify Research, discusses key trends in the specialty that she saw at the Radiological Society of North America's annual meeting. 

The New York-based imaging company is now focused on expanding sales for the cost-effective PET-CT system it developed with Neusoft Medical Systems.

The groups have jointly endorsed a unified framework “to standardize and harmonize quantitative PET imaging worldwide.”

The tracer's extended half-life of over three hours could make it a promising candidate for future prostate cancer diagnostics. 

The positive findings come after the U.S. Food and Drug Administration previously shared concerns related to sterility assurance issues during the drug’s production.